Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

1. A chromenone compound the Formula I:

an isomer thereof,

or a pharmaceutically acceptable salt thereof,

wherein R 1 represents hydrogen or alkyl;

each of R 2 , R 2 ′, R 3 and R 3 ′, independent of each other, represent hydrogen or alkyl; or

R 2 and R 3 together form —(CH 2 ) p —; and R 2 ′ and R 3 ′, independent of each other,

represent hydrogen or alkyl; wherein p is 1, 2 or 3;

m is 0, 1 or 2;

n is 0, 1 or 2;

X represents —O—; and

Q represents chromen-2-one-7-yl.

2. A pharmaceutical composition, comprising a therapeutically effective amount of the chromenone compound of claim 1 , or an isomer thereof, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.

3. A method for treatment or alleviation of a disease or a disorder or a condition of a living animal body, which disorder, disease or condition is selected from depression, anxiety and generalized anxiety disorder, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of the chromenone compound according to claim 1 , or an isomer thereof, or a pharmaceutically acceptable salt thereof.

4. The method according to claim 3 , wherein the chromenone compound according to claim 1 is exo-7-(8-H-8-aza-bicyclo[3.2.1]oct-3-yloxy)-chromen-2-one, or an isomer thereof, or a pharmaceutically acceptable salt thereof.

5. The chromenone compound of claim 1 , which is exo-7-(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-yloxy)-chromen-2-one;

7-(1-Methyl-piperidin-4-yloxy)-chromen-2-one;

7-(1,2,2,6,6-Pentamethyl-piperidin-4-yloxy)-chromen-2-one; or

7-(2,2,6,6-Tetramethyl-piperidin-4-yloxy)-chromen-2-one;

or a pharmaceutically acceptable salt thereof.